The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2019 | MRD assessment in CLL
Danielle Brander
• 2 Jun 2019
Measurable residual disease is playing a larger role in treatment assessment of chronic lymphocytic leukemia (CLL). This topic is explored by Danielle Brander, MD, of the Duke University School of Medicine, Durham, NC. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
